Acute effects of indacaterol on lung hyperinflation in moderate COPD: A comparison with tiotropium (original) (raw)

Abstract

Background: Evidence has been provided that high-dose indacaterol (300 mg) can reduce lung hyperinflation in moderate-to-severe chronic obstructive pulmonary disease (COPD). Aim: To study whether low-dose indacaterol (150 mg) also reduces lung hyperinflation in comparison with the recommended dose of tiotropium (18 mg) in moderate COPD. Methods: This was a multicenter, randomized, blinded, 3-period cross-over, placebocontrolled study. Spirometry and lung volumes were measured before and 30, 60, 120, 180 and 240 min after the administration of single-doses of indacaterol, tiotropium, or placebo. The primary end-point was the change in peak inspiratory capacity (IC). The area under the 4-h curve (AUC 0e4 ) for IC, 1-s forced expiratory volume (FEV 1 ) and forced vital capacity (FVC) were secondary variables. Results: 49 patients completed the study. On average, peak IC and AUC 0e4 for IC were significantly greater after indacaterol than placebo by 177 mL (p Z 0.007) and 142 mL (p Z 0.001), respectively. Differences in peak IC and AUC 0e4 for IC between tiotropium and placebo were 120 mL (p Z 0.07) and 85 mL (p Z 0.052), respectively. Differences between indacaterol and tiotropium were statistically insignificant. Peak IC increased by >20% in 12 patients with indacaterol and 9 with tiotropium (p Z 0.001), and by >30% in 8 patients with indacaterol Abbreviations: COPD, chronic obstructive pulmonary disease; LABA, long-acting beta-agonist. and 3 with tiotropium (p Z 0.001). The effects of indacaterol and tiotropium on FEV 1 and FVC were statistically significant vs placebo. Conclusions: Low-dose indacaterol has a bronchodilator effect that is similar to the recommended dose of tiotropium, but it is slightly superior in reducing lung hyperinflation. Trial registration: ClinicalTrials.gov number: NCT00999908. ª

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (40)

  1. GOLD Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, http://www.goldcopd. org/Guidelineitem.asp?l1Z2&l2Z1&intIdZ989; 2010.
  2. National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Clinical Guideline Centre. Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/English; 2010.
  3. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957e65.
  4. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778e84.
  5. Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, et al. Use of a long-acting inhaled beta-2 adren- ergic agonist, salmeterol xifonate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1087e92.
  6. Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058e69.
  7. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, et al. Improved health outcomes in patients with COPD during one year treatment with tiotropium. Eur Respir J 2002;19:205e6.
  8. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWalleck RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstuctive pulmonary disease. Eur Respir J 2002;19:217e24.
  9. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once-daily tiotropium compared with twice-daily salme- terol in patients with COPD. Thorax 2003;58:399e404.
  10. Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, et al. A dose ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008;102:1033e44.
  11. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, et al. Efficacy of a new once-daily long-acting inhaled beta2- agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010;65:473e9.
  12. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37:273e9.
  13. Donohue JF, Fogarty C, Lo ¨tvall J, Mahler DA, Worth H, Yorgancioglu A, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182:155e62.
  14. Cooper CB. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 2006;119(Suppl. 1):21e31.
  15. Milic-Emili J. Inspiratory capacity and exercise tolerance in chronic obstructive pulmonary disease. Can Respir J 2000;7:282e5.
  16. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:542e9.
  17. Diaz O, Villafranca C, Ghezzo H, Borzone G, Leiva A, Milic- Emil J, et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limi- tation at rest. Eur Respir J 2000;16:269e75.
  18. O'Donnell DE. Hyperinflation, dyspnea, and exercise intoler- ance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:180e4.
  19. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004;24:86e94.
  20. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124:1743e8.
  21. O'Donnell DE, Flu ¨ge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23:832e40.
  22. Beier J, Beeh KM, Brookman L, Peachey G, Hmissi A, Pascoe S. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009;22:492e6.
  23. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategy for lung function testing. Eur Respir J 2005;26:948e58.
  24. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardization of lung volumes. Eur Respir J 2005;26:511e22.
  25. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. ATS/ERS task force: standardization of spirometry. Eur Respir J 2005;26:319e38.
  26. Dal Vecchio L, Polegse G, Poggi R, Rossi A. Intrinsic positive and eexpiratory pressure in stable patients with chronic obstruc- tive pulmonary disease. Eur Resp J 1990;3:74e80.
  27. Tantucci C, Duguet A, Similowsky T, Zelter M, Derenne JP, Milic-Emili J. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998;12:799e804.
  28. Calverley PMA, Kolouris NG. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 2005;25:186e99.
  29. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1395e9.
  30. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:1557e65.
  31. O'Donnell DE. Assessment of bronchodilator efficacy in symp- tomatic COPD: is spirometry useful? Chest 2000;117:42Se7S.
  32. Pellegrino R, Rodarte JR, Brusasco V. Assessing the reversibility of airway obstruction. Chest 1998;114:1607e12.
  33. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374:1171e8.
  34. Santus P, Centanni S, Verga M, Di Marco F, Matera MG, Cazzola M. Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formo- terol on the degree of resting pulmonary hyperinflation. Respir Med 2006;100:1277e81.
  35. Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, et al. Blinded 12 week comparison of once daily indacaterol and tiotropium in COPD. Eur Respir J 2011. doi: 10.1183/09031936.00191810.
  36. Ofir D, Laveneziana P, Webb K, Lam Y-M, O'Donnell DE. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:622e9.
  37. O'Donnell DE, Laveneziana P, Webb KA, Lam Y-M, Ofir D. Evaluation of acute bronchodilator reversibility in patients with GOLD stage I COPD. Thorax 2009;64:216e23.
  38. Decramer M, Cooper CB. Treatment of COPD: the sooner the better? Thorax 2010;65:837e41.
  39. Balint B, Watz H, Amos C, Owen R, Higgins M, Kramer B. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis 2010;7:311e8.
  40. Calverley PM. New options for bronchodilator treatment in COPD. Thorax 2010;65:468e9.